六味能消胶囊联合兰索拉唑和莫沙必利治疗反流性食管炎的疗效观察

目的探究六味能消胶囊联合兰索拉唑和莫沙必利治疗反流性食管炎的临床疗效。方法选取2014年4月—2015年4月在山丹县人民医院接受治疗的反流性食管炎患者92例,随机分为对照组和治疗组,每组各46例。对照组患者早晨饭后口服兰索拉唑肠溶片,1片/次,1次/d;同时饭前口服枸橼酸莫沙必利片,1片/次,3次/d。治疗组患者在对照组的基础上饭后口服六味能消胶囊,1粒/次,3次/d。两组患者均每4周复查1次,连续治疗8周。治疗后,比较两组患者临床疗效、症状积分以及不良反应情况。结果治疗后,对照组和治疗组总有效率分别为71.74%和86.96%,两组总有效率比较差异具有统计学意义(P0.05)。治疗2、4、8周后,两组患者症状积分均较治疗前明显下降,同组治疗前后差异具有统计学意义(P0.05);且治疗8周后治疗组患者的症状改善情况明显优于对照组,两组比较差异具有统计学意义(P0.05)。两组不良反应发生率比较差异无统计学意义。结论六味能消胶囊联合兰索拉唑和莫沙必利治疗反流性食管炎疗效显著,能够显著抑制胃酸分泌,具有一定的临床推广应用价值。

Clinical observation of Liuwei Nengxiao Capsules combined with lansoprazole and mosapride in treatment of reflux esophagitis

Objective To explore clinical effect of Liuwei Nengxiao Capsules combined with lansoprazole and mosapride in treatment of reflux esophagitis. Methods Patients (92 cases) with reflux esophagitis in Shandan People''s Hospital from April 2014 to April 2015 were randomly divided into the control and treatment groups, and each group had 46 cases. The patients in the control group were po administered with Lansoprazole Enteric-coated Tablets after meals in the morning, 1 tablet/time, once daily. And they were po administered with Mosapride Citrate Tablets after meals, 1 tablet/time, three times daily. The patients in the treatment group were po administered with Liuwei Nengxiao Capsules after meals on the basis of the control group, 1 grain/time, three times daily. Patients in two groups were treated for 8 weeks and reviewed once every 4 weeks. After treatment, the clinical efficacy, main symptom scores and adverse reaction in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment group were 71.74% and 86.96%, respectively, and there were differences between two groups (P<0.05). After treatment for 2, 4, and 8 weeks, symptom scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the improvement of clinical symptom in treatment group treated for 8 weeks was better than that in the control group, with significant difference between two groups (P<0.05). There was no significant difference in adverse reactions rate between two groups. Conclusion Liuwei Nengxiao Capsules combined with lansoprazole and mosapride has a significant clinical effect in treatment of reflux esophagitis, can obviously inhibited the secretion of gastric acid, which has a certain clinical application value.